Beclin 1 (encoded by the BECN1 gene) is a core scaffold protein in the Class III phosphatidylinositol 3-kinase (PI3K) complex, serving as a master regulator of autophagy and programmed cell death. Because it coordinates autophagosome nucleation, Beclin 1 is a high-value therapeutic target across oncology, neurodegenerative diseases, and infectious diseases.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for Beclin 1/BECN1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Beclin 1 (BECN1) Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. Ideal for PPI and binding assays. |
View BECN1 Products |
| Gene Delivery | Beclin 1 (BECN1) Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and autophagic flux assays. |
View BECN1 Products |
| Benchmark Ab | Anti-Beclin 1 (BECN1) Benchmark Antibody Recombinant positive control for Western Blot, IHC, and IP validation. |
View BECN1 Products |
| Validator | Beclin 1 (BECN1) siRNA Set For target knockdown verification and specificity profiling. |
View BECN1 Products |
| Related Target A | BCL2 Interacts directly with the BH3 domain of Beclin 1 to inhibit autophagy; key target for PPI disruption. |
View BCL2 Products |
| Related Target B | PIK3C3 (VPS34) Core catalytic subunit of the Class III PI3K complex that binds Beclin 1 to generate PI3P. |
View PIK3C3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Protein-Protein Interaction (PPI) Screening | High-purity human Beclin 1 and BCL2 proteins strictly verified by mass spectrometry for robust SPR/BLI assays. |
| Autophagy Flux Monitoring | Lentiviral vectors for stable overexpression of wild-type and functional domain mutants of Beclin 1. |
| Lack of Controls | Recombinant benchmark antibodies included for reproducible positive controls. |
| False Positives in Knockdown | Sequence-verified siRNA pools included for specific gene knockdown validation. |
Live Beclin 1/BECN1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic modulation of Beclin 1 is gaining significant momentum. In neurodegenerative diseases like Alzheimer's and Parkinson's, upregulating Beclin 1 activity promotes the clearance of toxic protein aggregates (amyloid-beta, alpha-synuclein). Conversely, in advanced cancers, autophagy acts as a survival mechanism for tumor cells under metabolic stress, making Beclin 1 inhibition a viable strategy to overcome drug resistance.
The race for Beclin 1 therapeutics is intensifying, with major players shifting focus from traditional gene therapies to cell-permeable peptide mimetics and small-molecule PPI (Protein-Protein Interaction) disruptors. As first-generation therapies reach the clinic, the next wave of R&D is targeting the precise spatial regulation of the Beclin 1-VPS34-ATG14 complex.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Peptide Mimetics (e.g., Tat-Beclin 1) | Academic Spin-offs, Biotech Startups | Infectious Diseases, Neurodegeneration | Autophagy Induction Assay (Need Lentivirus for stable cell line generation) |
| Small Molecule PPI Disruptors | Oncology-focused Biopharma | Solid Tumors, Drug-Resistant Cancers | In vitro Binding & Competition Assays (Need high-purity Beclin 1 & BCL2 proteins) |
| Gene Therapy (AAV/Lentivirus) | Neurology Biotechs | Alzheimer's Disease, Parkinson's Disease | Expression & Localization Assays (Need sequence-verified ORF clones and antibodies) |